Crescent Biopharma (CBIO) Depreciation & Amortization (CF) (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $64000.0 in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $64000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $148000.0 (up 1091.34% YoY), and the FY2025 annual result was $84000.0, up 138.81% from the prior year.
• Depreciation & Amortization (CF) improved to $64000.0 in Q1 2026 per CBIO's latest filing, from $54000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $64000.0 in Q1 2026 and troughed at $2000.0 in Q2 2025.
• A 5-year average of $38249.4 and a median of $43629.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) dropped 9.72% in 2023, then plunged 83.9% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $45718.0 in 2022, then slumped by 49.04% to $23297.0 in 2023, then sank by 46.68% to $12423.0 in 2024, then soared by 334.68% to $54000.0 in 2025, then advanced by 18.52% to $64000.0 in 2026.
• Business Quant data shows CBIO's Depreciation & Amortization (CF) at $64000.0 in Q1 2026, $54000.0 in Q4 2025, and $28000.0 in Q3 2025.